Illumina Plunges as Consumables Drop Tests High Valuation

• Our read: EasyAlpha gives Illumina Inc a B grade, reflecting good quality that scores better than most industry peers, with profitability ranking as its strongest dimension and valuation as its key watch item.
• The day: Shares fell 18.6% to close at $235.99 after third-quarter results revealed shrinking research consumables demand and softer underlying growth.
• Watching: The consensus analyst target of $248.90 as Wall Street reviews its growth projections.

Illumina experienced sharp selling on Friday, with shares plunging 18.6% in their largest single-day drop since Friday, October 31, 2025. Trading volume climbed to 2.3x the 20-session average as investors reacted to the company's latest quarterly update.

The selloff followed an earnings release where Illumina raised full-year revenue guidance and reported tariff-adjusted revenue. However, the market focused on a revenue miss on a reported basis, and operational details troubled investors. Company filings revealed that research and applied consumables declined 6%, while fourth-quarter rest-of-world organic growth was forecast at roughly 4.5%. Adding to the pressure, investors confronted concerns about China growth and the broader pace of expansion. Executives reviewed third-quarter results during the earnings call, but the weakness in consumables dominated the market's response.

Illumina brought an EasyAlpha grade of B into Friday's session, scoring better than most industry peers. In historical testing, companies graded A or B have delivered stronger fundamentals and experienced fewer steep drawdowns than those graded D or E. Across its reported operations, the company generates a 18.3% profit margin and a return on equity of 32.3%.

The friction that surfaced on Friday centers on valuation. Even after the selloff, Illumina trades at 45.5 times forward earnings. Rich valuation multiples leave little room for operational hiccups, and slowing demand in higher-margin consumables prompted investors to reassess that premium. The drop leaves the stock -12.4% over the past week, though it remains +79.9% so far this year.

Wall Street has leaned positive on the name, with 52.4% of the 21 analysts tracked by EasyAlpha rating the stock a buy. Their average price target of $248.90 sits above Friday's closing level. Rebuilding upward momentum will likely require Illumina to prove that the consumables slump is temporary and that new instrument placements can reignite overall sequencing revenue.